Home / Companies / News / Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.

The government is now trying to understand how long it will take before the drug’s production can start in India

Premium

In 2016 the company had started working on this botanical medicine with the Department of Biotechnology- International Centre for Genetic Engineering and Biotechnology ( DBT-ICGEB) and the Council of Scientific and Industrial Research- Indian Institu

Sohini Das Mumbai

3 min read Last Updated : Jun 05 2020 | 10:38 PM IST

India's largest drugmaker Sun Pharmaceutical Industries said on Friday that it has commenced phase II clinical trials on AQCH, a plant-derived drug that was originally developed for dengue, to see if it can potentially treat Covid-19.

The trial will be conducted across 12 centres in India on 210 patients. This is also the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19. The company said that the results of the trial are expected by October this year. “Human safety study of AQCH has already been completed and the drug has been found

Topics : Coronavirus Sun Pharma Dengue clinical trials Pharma Companies pharmaceutical industry

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in